AXOGEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.52 USD | -2.46% |
|
+3.30% | +10.10% |
| Jul. 01 | Raymond James Initiates AxoGen at Outperform With $13 Price Target | MT |
| Jun. 24 | Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 706.1 | 718.3 | 389.4 | 422 | 294 | 328.7 | - | - |
| Enterprise Value (EV) 1 | 706.1 | 718.3 | 389.4 | 422 | 294 | 328.7 | 328.7 | 328.7 |
| P/E ratio | -24.2 x | -29.8 x | -14.4 x | -14.5 x | -13.4 x | -16.2 x | -43.6 x | 33.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.62 x | 6.4 x | 3.06 x | 3.05 x | 1.85 x | 1.84 x | 1.63 x | 1.46 x |
| EV / Revenue | 6.62 x | 6.4 x | 3.06 x | 3.05 x | 1.85 x | 1.84 x | 1.63 x | 1.46 x |
| EV / EBITDA | -23.2 x | -33.3 x | -19.5 x | -45.6 x | -262 x | 27.8 x | 15.9 x | 8.01 x |
| EV / FCF | - | - | - | -11.7 x | -15 x | -54.3 x | 91.3 x | 13.4 x |
| FCF Yield | - | - | - | -8.56% | -6.66% | -1.84% | 1.1% | 7.48% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 39,469 | 40,126 | 41,563 | 42,287 | 43,044 | 43,705 | - | - |
| Reference price 2 | 17.89 | 17.90 | 9.370 | 9.980 | 6.830 | 7.520 | 7.520 | 7.520 |
| Announcement Date | 2/24/20 | 2/22/21 | 2/22/22 | 3/14/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 106.7 | 112.3 | 127.4 | 138.6 | 159 | 178.8 | 201.6 | 224.6 |
| EBITDA 1 | -30.47 | -21.6 | -19.94 | -9.259 | -1.12 | 11.8 | 20.7 | 41.03 |
| EBIT 1 | -31.41 | -23.18 | -25.42 | -29.71 | -21.46 | -14.16 | -0.675 | 24.26 |
| Operating Margin | -29.43% | -20.64% | -19.96% | -21.44% | -13.5% | -7.92% | -0.33% | 10.8% |
| Earnings before Tax (EBT) 1 | -29.14 | -23.79 | -26.98 | -28.95 | -21.72 | -16.51 | 4.888 | 20.91 |
| Net income 1 | -29.14 | -23.79 | -26.98 | -28.95 | -21.72 | -20.28 | -5.608 | 17.66 |
| Net margin | -27.3% | -21.18% | -21.19% | -20.89% | -13.66% | -11.34% | -2.78% | 7.86% |
| EPS 2 | -0.7400 | -0.6000 | -0.6500 | -0.6900 | -0.5100 | -0.4650 | -0.1725 | 0.2233 |
| Free Cash Flow 1 | - | - | - | -36.14 | -19.59 | -6.05 | 3.6 | 24.6 |
| FCF margin | - | - | - | -26.08% | -12.32% | -3.38% | 1.79% | 10.95% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 17.39% | 59.95% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 139.29% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/20 | 2/22/21 | 2/22/22 | 3/14/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 31.54 | 31.01 | 34.45 | 36.96 | 36.16 | 36.66 | 38.16 | 41.27 | 42.92 | 41.38 | 43.33 | 46.35 | 47.77 | 47.11 | 48.65 |
| EBITDA 1 | -3.669 | -7.357 | -1.587 | 0.368 | -0.683 | -3.79 | -0.246 | 2.354 | 0.567 | 1.002 | 2.686 | 3.872 | 4.246 | 1.288 | 3.077 |
| EBIT 1 | -5.353 | -11.32 | -7.924 | -4.855 | -5.608 | -7.341 | -6.902 | -4.025 | -3.194 | -4.56 | -4.418 | -3.033 | -2.192 | -4.515 | -3.476 |
| Operating Margin | -16.97% | -36.51% | -23% | -13.14% | -15.51% | -20.02% | -18.09% | -9.75% | -7.44% | -11.02% | -10.2% | -6.54% | -4.59% | -9.58% | -7.14% |
| Earnings before Tax (EBT) 1 | -5.286 | -11.48 | -7.74 | -4.318 | -5.415 | -7.074 | -6.66 | -4.089 | -3.893 | -6.635 | -4.503 | -3.251 | -2.364 | -2.655 | -1.376 |
| Net income 1 | -5.286 | -11.48 | -7.74 | -4.318 | -5.415 | -7.074 | -6.66 | -4.089 | -3.893 | -6.635 | -5.402 | -4.363 | -3.882 | -5.828 | -4.688 |
| Net margin | -16.76% | -37.01% | -22.46% | -11.68% | -14.97% | -19.29% | -17.46% | -9.91% | -9.07% | -16.04% | -12.47% | -9.41% | -8.13% | -12.37% | -9.64% |
| EPS 2 | -0.1300 | -0.2700 | -0.1800 | -0.1000 | -0.1300 | -0.1700 | -0.1600 | -0.1000 | -0.0900 | -0.1500 | -0.1225 | -0.1000 | -0.0875 | -0.1300 | -0.1050 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/22/22 | 5/4/22 | 8/3/22 | 11/8/22 | 3/14/23 | 5/9/23 | 8/7/23 | 11/7/23 | 3/5/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -36.1 | -19.6 | -6.05 | 3.6 | 24.6 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 21.9 | 27.8 | 20.1 | 13.9 | 3.9 | 3.5 | 5 |
| Capex / Sales | - | 19.51% | 21.84% | 14.49% | 8.72% | 2.18% | 1.74% | 2.23% |
| Announcement Date | 2/24/20 | 2/22/21 | 2/22/22 | 3/14/23 | 3/5/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.52
USD
Average target price
13.33
USD
Spread / Average Target
+77.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.10% | 329M | |
| +0.59% | 204B | |
| +3.92% | 178B | |
| +30.07% | 156B | |
| +32.42% | 113B | |
| +1.75% | 64.26B | |
| +19.65% | 54.98B | |
| -1.86% | 47.44B | |
| -9.53% | 36.7B | |
| -1.28% | 34.84B |
- Stock Market
- Equities
- AXGN Stock
- Financials AxoGen, Inc.
